# Profoundd archive — Epstein Files
# Bates number: EFTA02275773
# Title:        To: Jefffrey Epstein[jeevacation©gmail.con]; Rich Kahn
# Dataset:      11
# Pages:        2
# Tags:         epstein, doj, dataset-11
# Source PDF:   https://profoundd.com/epstein-docs/EFTA02275773/download
# Doc viewer:   https://profoundd.com/epstein-docs/EFTA02275773
#
# Text below is what Profoundd has extracted from the source PDF.
# 'ocr-enriched' tag means OCR was applied to scan-only pages.
# Image descriptions are AI-generated factual captions (llava:13b).
#----------------------------------------------------------------------

=== SUMMARY ===
To: Jefffrey Epstein[jeevacation©gmail.con]; Rich Kahn From: Lesley Groff Sent: Thur 1/17/2019 5:19:49 PM Subject: Fo From: < r toksjaySsam a > To: jeevacation@gmaitcom <jeevacationeinmait.com>;I requested I forward you the below `catch up' email. Sent: Wednesday, January 16, 2019, 11:22:06 PM EST Subject: Catching Up Dear Jeffrey I hope you've been well. I wanted to update you on what I've been up to for the last two years. I was also hoping to talk with you to sec if I might use the foundation


=== EXTRACTED TEXT ===
To: Jefffrey Epstein[jeevacation©gmail.con]; Rich Kahn 
From: Lesley Groff 
Sent: Thur 1/17/2019 5:19:49 PM 
Subject: 
 Fo 
From: < r toksjaySsam a > 
To: jeevacation@gmaitcom  <jeevacationeinmait.com>;I 
requested I forward you the below `catch up' email. 
Sent: Wednesday, January 16, 2019, 11:22:06 PM EST 
Subject: Catching Up 
Dear Jeffrey 
I hope you've been well. I wanted to update you on what I've been up to for the last two 
years. I was also hoping to talk with you to sec if I might use the foundation's 
Lexington office conference room from time to time for my work and what I could 
provide in exchange for that. I am cc'ing Rich because I'm not sure if you still use 
this email? 
Since working for your foundation, I continued to publish as a journalist writing mostly 
about genetic vectors (Newsweek, Techonomy etc). I then set up an LLC that 
provides business development for labs that have reversed age-driven or 
degenerative diseases. Most of the therapies are genetic vectors, and have to show 
remarkable results at the mouse level and beyond. Regenerative medicine is a 
rapidly evolving field, and one that forces the medical industry to shift their focus 
from addressing symptoms of disease to fundamental evolutionary shortfalls. 
So far, I placed a genetic vector at the National Institute of Medicine in France (that 
EFTA_R1_01089814 
EFTA02275773
reversed glaucoma in mice using the neuroglobin gene) under formal licence 
review with a publicly traded pharma group here in the US. And I am collaborating 
with a lab at the University of Pittsburgh that has reversed cirrhosis/ end stage liver 
disease in rats using the master transcription gene in hepatocytes. The concept of 
the latter gene vector is really intriguing in that a master transcription gene 
completely restored liver function by rebalancing genetic expression and thus 
proteostasis. 
While I don't really need an office at this point, I do need access to a conference room 
from time to time and it would be hugely helpful if I could access the foundation's. 
If there was some work that I could do for the foundation in exchange, I would be 
delighted to do that. 
It would be wonderful to catch up with you as well. 
all the best, 
EFTA_R1_01089815 
EFTA02275774